Rhythm Pharmaceuticals Inc [RYTM] stock prices are down -0.05% to $100.77 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RYTM shares have gain 2.97% over the last week, with a monthly amount glided 4.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $97. Previously, Leerink Partners started tracking the stock with Outperform rating on July 07, 2025, and set its price target to $88. On April 07, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $63 on the stock. Jefferies initiated its recommendation with a Buy and recommended $80 as its price target on January 02, 2025. Oppenheimer started tracking with a Outperform rating for this stock on December 20, 2024, and assigned it a price target of $76. In a note dated October 21, 2024, Guggenheim initiated an Buy rating and provided a target price of $70 on this stock.
The stock price of Rhythm Pharmaceuticals Inc [RYTM] has been fluctuating between $45.90 and $106.52 over the past year. Currently, Wall Street analysts expect the stock to reach $113.6 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $100.77 at the most recent close of the market. An investor can expect a potential return of 12.73% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
The Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 156.29M for trailing twelve months, representing a surge of 66.80%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.14%, Pretax Profit Margin comes in at -1.17%, and Net Profit Margin reading is -1.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.19 and Total Capital is -0.73. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Rhythm Pharmaceuticals Inc [NASDAQ:RYTM]’s Current Ratio is 2.79. On the other hand, the Quick Ratio is 2.64, and the Cash Ratio is 1.05. Considering the valuation of this stock, the price to sales ratio is 42.83.
Transactions by insiders
Recent insider trading involved Shulman Joseph, Chief Technical Officer, that happened on Sep 02 ’25 when 16781.0 shares were sold. Officer, JOSEPH SHULMAN completed a deal on Sep 02 ’25 to buy 16781.0 shares. Meanwhile, Chief Technical Officer Shulman Joseph sold 4188.0 shares on Aug 21 ’25.
